Boehringer mental health tie-up worth up to $126.5 million to Broad Institute

Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, are collaborating on a project to tackle the urgent and unmet needs of people living with mental health conditions.

The collaboration will focus on developing first-in-class treatments that address sleep disturbances associated with cognitive impairment in mental health conditions such as schizophrenia or mood disorders, which have a substantial impact on those affected, but also on their care partners and families.

One in eight people are currently living with a serious mental health condition worldwide, and one in two will experience such a condition in their lifetime.